Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

11.99 +0.61 (+5.36%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,457,483
Open 11.45
Bid (Size) 11.85 (200)
Ask (Size) 11.99 (400)
Prev. Close 11.38
Today's Range 11.42 - 12.19
52wk Range 2.600 - 16.96
Shares Outstanding 67,176,067
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? ↗
A late-stage biotech with three pivotal trials underway just landed a major hedge-fund backer — here’s why the timing matters. 
Via The Motley Fool
News headline image
Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow? ↗
Amylyx Stock is up a staggering 166% over the past year, and this biotech-focused hedge fund is still doubling down. 
Via The Motley Fool

Performance

YTD
+5.0%
+5.0%
1 Month
-12.3%
-12.3%
3 Month
-11.1%
-11.1%
6 Month
+71.8%
+71.8%
1 Year
+205.9%
+205.9%

More News

Read More
News headline image
Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
News headline image
Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover ↗
Via The Motley Fool
News headline image
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX
From Rosen Law Firm
Via Business Wire
News headline image
Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Avantor, Inc. (NYSE: AVTR); Humana Inc. (NYSE: HUM); and Maison Solutions Inc. (NASDAQ: MSS): Grabar Law Office Investigates Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
News headline image
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) Narrows Q3 2025 Loss, Bolsters Cash Runway to 2028 ↗
Via Chartmill
News headline image
Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Five Below, Inc. (NASDAQ: FIVE); Humana Inc. (NYSE: HUM); and Treace Medical Concepts (NASDAQ: TMCI): Grabar Law Office Investigates Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
News headline image
Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via Business Wire
News headline image
Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Baxter International Inc. (NYSE: BAX); Five Below, Inc. (NASDAQ: FIVE); and Humana Inc. (NYSE: HUM): Grabar Law Office Investigates Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
News headline image
Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Baxter International Inc. (NYSE: BAX); Five Below, Inc. (NASDAQ: FIVE); and Humana Inc. (NYSE: HUM): Grabar Law Office is Investigating Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
News headline image
Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Hertz Global Holdings, Inc. (NASDAQ: HTZ): Grabar Law Office is Investigating Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
News headline image
AMYLYX INVESTIGATION: Bragar Eagel & Squire, P.C. Urges Amylyx Investors to Contact the Firm Regarding Ongoing Investigation into Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
News headline image
Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire

Frequently Asked Questions

Is Amylyx Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Amylyx Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Amylyx Pharmaceuticals, Inc. - Common Stock trade on?
Amylyx Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Amylyx Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Amylyx Pharmaceuticals, Inc. - Common Stock is AMLX on the Nasdaq Stock Market
What is the current price of Amylyx Pharmaceuticals, Inc. - Common Stock?
The current price of Amylyx Pharmaceuticals, Inc. - Common Stock is 11.99
When was Amylyx Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Amylyx Pharmaceuticals, Inc. - Common Stock was at 01/07/26 04:00 PM ET
What is the market capitalization of Amylyx Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Amylyx Pharmaceuticals, Inc. - Common Stock is 805.44M
How many shares of Amylyx Pharmaceuticals, Inc. - Common Stock are outstanding?
Amylyx Pharmaceuticals, Inc. - Common Stock has 805M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.